GFRA2 (GDNF Family Receptor Alpha 2, also known as GFRα2) is a critical GPI-anchored cell surface receptor that mediates the biological effects of neurturin (NRTN) and other GDNF family ligands. As a key component of the GDNF family signaling system, GFRA2 plays essential roles in the development, survival, and maintenance of dopaminergic neurons, motor neurons, and peripheral neurons.
In the context of neurodegenerative diseases, the GFRA2/neurturin signaling axis has been extensively studied as a therapeutic target for Parkinson's disease, with clinical trials investigating gene therapy approaches to deliver neurotrophic support to degenerating dopaminergic neurons[1][2].
The GFRA2 receptor is a member of the GDNF receptor alpha (GFRα) family, which includes four related proteins (GFRα1-4) that serve as high-affinity receptors for GDNF family ligands[3]:
| Receptor | Primary Ligand | Other Ligands |
|---|---|---|
| GFRα1 | GDNF | Artemin, Persephin |
| GFRα2 | Neurturin | Persephin |
| GFRα3 | Artemin | — |
| GFRα4 | GDNF-like (fish) | — |
GFRA2 is unique among the GFRα family for its restricted expression pattern and specific role in neuronal survival. It signals primarily through the RET receptor tyrosine kinase to activate pro-survival pathways including PI3K/Akt and MAPK/ERK[4].
GFRA2 is a approximately 40-45 kDa GPI-anchored protein with distinct structural features:
| Domain | Amino Acids | Function |
|---|---|---|
| Signal peptide | 1-21 | Secretory pathway targeting |
| Propeptide | 22-29 | Processing |
| Extracellular domain | 30-330 | Ligand binding |
| LFHL domains | 60-330 | Three homologous modules |
| GPI anchor | C-terminus | Membrane attachment |
GFRA2 binds neurturin with high affinity (Kd ~10-20 pM) through its extracellular domain:
GFRA2 undergoes several modifications:
GFRA2 mediates neurturin signaling through two primary mechanisms [5][6]:
When neurturin binds to GFRA2:
PI3K/Akt Pathway:
MAPK/ERK Pathway:
In the normal nervous system, GFRA2/neurturin signaling supports [7]:
Dopaminergic Neuron Survival
Motor Neuron Function
Enteric Nervous System
Peripheral Neurons
Non-neuronal Functions
GFRA2/neurturin is one of the most studied neurotrophic systems in PD [8][9]:
Rationale for therapy:
Clinical trials:
Current status:
GFRA2 in ALS [10]:
Motor neuron support:
Therapeutic potential:
Peripheral neuropathies:
Enteric neurodegeneration:
| Approach | Agent | Status | Mechanism |
|---|---|---|---|
| Gene therapy | AAV2-NRTN (CERE-120) | Completed trials | Neurturin overexpression |
| Protein delivery | Recombinant NRTN | Research | Direct protein administration |
| Small molecules | RET agonists | Preclinical | Activate downstream signaling |
| Cell therapy | NRTN-expressing cells | Research | Localized delivery |
Key challenges in targeting GFRA2 for neurodegeneration [11]:
| Biomarker | Sample | Significance |
|---|---|---|
| GFRA2 expression | Brain tissue | Maintained in PD SNc |
| NRTN levels | CSF | Potential marker |
| p-AKT signaling | Blood/CSF | Downstream activation |
| RET phosphorylation | Models | Pathway activation |
GFRA2 biomarkers may indicate:
GFRA2 intersects with multiple neurodegenerative pathways [12]:
The study of Gfra2 Gdnf Family Receptor Alpha 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bartus RT, Johnson EM Jr. "Clinical tests of neurotrophic factors for human neurodegenerative diseases." Neurobiology of Disease. 2017;97:97-109. Neurobiology of Disease. 2017. ↩︎
- Paratcha G, Ibáñez CF. "GDNF and GFRα: a versatile neuronal unit signaling machine." Nature Reviews Neuroscience. 2002;3(5):382-394. Nature Reviews Neuroscience. 2002. ↩︎
-邮箱:TDwells J, Barker RA. "Clinical trials of neurotrophic factors for Parkinson's disease." Movement Disorders. Movement Disorders. 2019. ↩︎